COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AJ3O
|
|||
| Drug Name |
PMID27240464-compound-3f
|
|||
| Synonyms |
PMID27240464-C-3f
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | Severe acute respiratory syndrome (SARS) | Preclinical | [1] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV 3C-like proteinase (3CLpro) | Target Info | Inhibitor | [1] |
| Compound 3f serves as a broad-spectrum antiviral agent with low micromolar inhibitory activity against 3CL(pro) of SARS-CoV and MERS-CoV. | ||||
| SARS-CoV 3C-like protease (3CLpro) | Target Info | Inhibitor | [1] | |
| Compound 3f serves as a broad-spectrum antiviral agent with low micromolar inhibitory activity against 3CL(pro) of SARS-CoV and MERS-CoV. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.